Citrine Approved to Launch Rare Disease Drug in China without Clinical Trial

Citrine Medicine, a Shanghai-Boston rare disease company, received a waiver to market a treatment for narcolepsy in China without a clinical trial. Six months ago, Citrine acquired China rights to Wakix® (pitolisant), a drug already approved in the EU and US to treat narcolepsy in adult patients with and without cataplexy. Citrine will file an NDA in China using data from the US and Europe . Citrine's $80 million Series A round was led by Quan Capital. More details.... Share this with colleagues: // //